Evidence map›Paper›PMID 34685477›Full record

ArticleLife (Basel, Switzerland)2021

Cell Populations Expressing Stemness-Associated Markers in Lung Adenocarcinoma.

Claudia Paterson, Ethan J Kilmister, Helen D Brasch, Nicholas Bockett, Josie Patel, Erin Paterson, Gordon Purdie, Sean Galvin, Paul F Davis, Tinte Itinteang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Claudia PatersonGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Ethan J KilmisterGillies McIndoe Research Institute, Wellington 6242, New Zealand.ORCID 0000-0002-8574-6877
Helen D BraschGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Nicholas BockettGillies McIndoe Research Institute, Wellington 6242, New Zealand.ORCID 0000-0002-7630-7637
Josie PatelGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Erin PatersonGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Gordon PurdieBiostatistical Group, Dean's Department, University of Otago, Wellington 6021, New Zealand.
Sean GalvinGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Paul F DavisGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Tinte ItinteangGillies McIndoe Research Institute, Wellington 6242, New Zealand.
Swee T TanGillies McIndoe Research Institute, Wellington 6242, New Zealand.ORCID 0000-0002-0695-453X
Gillies McIndoe Research Institute · NZThe Royal Melbourne Hospital · AUUniversity of Otago · NZWellington Hospital · NZ

Funding

Deane Endowment Trust the Summer Student scholarship
6 · The paper itself

Abstract

The stemness-associated markers OCT4, NANOG, SOX2, KLF4 and c-MYC are expressed in numerous cancer types suggesting the presence of cancer stem cells (CSCs). Immunohistochemical (IHC) staining performed on 12 lung adenocarcinoma (LA) tissue samples showed protein expression of OCT4, NANOG, SOX2, KLF4 and c-MYC, and the CSC marker CD44. In situ hybridization (ISH) performed on six of the LA tissue samples showed mRNA expression of OCT4, NANOG, SOX2, KLF4 and c-MYC. Immunofluorescence staining performed on three of the tissue samples showed co-expression of OCT4 and c-MYC with NANOG, SOX2 and KLF4 by tumor gland cells, and expression of OCT4 and c-MYC exclusively by cells within the stroma. RT-qPCR performed on five LA-derived primary cell lines showed mRNA expression of all the markers except SOX2. Western blotting performed on four LA-derived primary cell lines demonstrated protein expression of all the markers except SOX2 and NANOG. Initial tumorsphere assays performed on four LA-derived primary cell lines demonstrated 0-80% of tumorspheres surpassing the 50 µm threshold. The expression of the stemness-associated markers OCT4, SOX2, NANOG, KFL4 and c-MYC by LA at the mRNA and protein level, and the unique expression patterns suggest a putative presence of CSC subpopulations within LA, which may be a novel therapeutic target for this cancer. Further functional studies are required to investigate the possession of stemness traits.

Indexed as

cancer stem cellsembryonic stem cellsinduced pluripotent stem cellslung adenocarcinomastemness-associated markerstreatment resistancetumorsphere

Identifiers

PMID34685477
PMCPMC8541371
OpenAlexW3206298437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.